Matrix Metalloproteinase 13 Is Associated with Age-Related Choroidal Neovascularization

Jorge González-Zamora1, María Hernandez2, Sergio Recalde2

  • 1Retinal Pathologies and New Therapies Group, Experimental Ophthalmology Laboratory, Department of Ophthalmology, Clinica Universidad de Navarra, 31008 Pamplona, Spain.

Insights

Matrix metalloproteinase-13 (MMP13) is implicated in age-related macular degeneration (AMD). MMP13 expression increased in AMD models, but plasma levels were lower in patients, suggesting complex roles in this vision-impairing disease.

Area of Science:

  • Ophthalmology
  • Cell Biology
  • Biochemistry

Background:

  • Age-related macular degeneration (AMD) is a primary cause of vision loss in developed nations.
  • The underlying pathophysiology of AMD is not fully understood.
  • Matrix metalloproteinases (MMPs) are potential contributors to AMD development.

Purpose of the Study:

  • To characterize the role and expression of MMP-13 in age-related macular degeneration.
  • Investigate MMP-13 in retinal pigment epithelial cells, a murine model, and patient plasma.

Main Methods:

  • Utilized cultured retinal pigment epithelial cells subjected to oxidative stress.
  • Employed a murine model of laser-induced choroidal neovascularization.
  • Analyzed plasma samples from patients with neovascular AMD and healthy controls.

Main Results:

  • MMP13 expression significantly increased in retinal pigment epithelial cells under oxidative stress.
  • MMP13 was overexpressed in retinal pigment epithelial and endothelial cells during choroidal neovascularization in mice.
  • Plasma MMP13 levels were significantly lower in patients with neovascular AMD compared to controls.

Conclusions:

  • MMP13 expression is altered in AMD, increasing under stress and during neovascularization.
  • Lower plasma MMP13 levels in AMD patients may indicate reduced diffusion or release from compromised monocytes.
  • MMP-13 presents a potential therapeutic target for age-related macular degeneration.